NCT03316573 2026-02-10
Pembrolizumab in Neoplasms or Lymphomas
Dana-Farber Cancer Institute
Phase 2 Suspended
Dana-Farber Cancer Institute
Dana-Farber Cancer Institute
Baylor College of Medicine
Maria Sklodowska-Curie National Research Institute of Oncology